IOncology

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI) took place from January 23 to 25 in San Francisco, bringing together the latest advancements in digestive tract oncology. Paclitaxel remains one of the most important chemotherapeutic agents for gastric cancer treatment. However, the traditional intravenous (IV) formulation has long been associated with significant adverse effects. Chinese researchers have continued to optimize the structure and formulation of paclitaxel, aiming for better efficacy and safety, ultimately leading to the successful development and approval of the world's first oral paclitaxel solution.

In the field of breast cancer, the treatment of patients with BRCA gene mutations has always been a research hotspot. Recently, at the SABCS conference, Professor Matteo Lambertini from the San Martino Hospital of the University of Genoa, Italy, shared the latest findings on the treatment of BRCA-mutated breast cancer in depth (abstract number: GS1-08). This study aims to explore the impact of risk-reducing surgeries (including prophylactic mastectomy and prophylactic salpingo-oophorectomy) on the survival outcomes of young patients with BRCA-mutated breast cancer. The researchers collected and analyzed data from 5,290 young patients with BRCA-mutated breast cancer from 109 centers worldwide, providing important evidence for the cancer risk management strategies of this specific patient population. Oncology Frontier interviewed Professor Matteo Lambertini on-site at the SABCS conference and invited him to share the highlights of the conference that he focused on.

The VHL-HIF pathway is one of the most commonly activated pathways in clear cell renal cell carcinoma (ccRCC). Loss of von Hippel-Lindau (VHL) gene function leads to the stabilization of hypoxia-inducible factors HIF-1α and HIF-2α, driving tumor growth and progression. The development of HIF-2α inhibitors, including belzutifan and casdatifan, has introduced new therapeutic strategies for ccRCC.At the 2025 ASCO GU Annual Meeting, Professor Toni Choueiri from Dana-Farber Cancer Institute presented phase I study results on casdatifan, offering insights into its clinical activity and potential role in renal cell carcinoma treatment.

From August 5th to 10th, 2024, the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Provincial Colorectal Cancer Academic Conference were held in Guangzhou. During the event, Dr. Jin Gu from Peking University Shougang Hospital shared important insights and conclusions from his center’s experience with combined pelvic organ resection surgery for refractory rectal cancer. After the conference, we had the privilege of interviewing Professor Gu.

Hormone receptor-positive (HR+) breast cancer is the most common subtype of breast cancer, with approximately 40% of these patients harboring a PI3KCA mutation. This mutation is a primary cause of resistance to endocrine therapy and CDK4/6 inhibitors, leading to poorer prognosis for affected patients. At the 2024 CSCO Annual Meeting, Dr. Jiong Wu from Fudan University Shanghai Cancer Center, as the Leading PI, shared the latest findings from the Phase III INAVO120 study. The study demonstrated that the novel PI3K inhibitor, inavolisib, combined with CDK4/6 inhibitors and endocrine therapy, offers improved outcomes for these patients, providing a new treatment option. Based on these results, both the China National Medical Products Administration (CDE) and the U.S. FDA have granted fast-track review status to inavolisib, with hopes of delivering clinical benefits to patients soon. At the CSCO meeting, Oncology Frontier had the opportunity to interview Professor Wu, discussing key insights about inavolisib and providing clinical guidance on this emerging PI3K inhibitor.

Presented at the ASCO GU Annual Symposium (February 13–15, 2025), San FranciscoThe EV-302 (KEYNOTE-A39) trial provided new insights into enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy in previously untreated…

Presented at the 2024 ASCO Annual Meeting on June 5, the SACI-IO HR+ trial investigated sacituzumab govitecan (SG) with or without pembrolizumab in patients with hormone receptor-positive/HER2-negative metastatic breast cancer…

Published on March 21, 2024, in the Journal of Clinical Oncology, the PACE trial explored whether continuing CDK4/6 inhibitors (CDK4/6i) with endocrine therapy beyond progression could benefit patients with hormone…

Healthy living for all, together we uphold, and start a new chapter! September is the National Healthy Lifestyle Promotion Month. We focus on breast cancer, a significant disease threatening women's health, and have specially invited authoritative experts in the field of breast cancer from China to discuss the scientific prevention and treatment of breast cancer and the importance of a healthy lifestyle. The experts unanimously emphasize that facing the disease scientifically, actively preventing it, and treating it precisely are the keys to overcoming breast cancer. Let us join hands with a scientific attitude and firm belief to protect the beauty and dignity of life, and promote breast cancer prevention and treatment to new heights, contributing to the great goal of a Healthy China! We hope that through the experts' interpretations, we can not only enhance the public's understanding of breast cancer but also encourage patients and their families to actively participate in screening and advocate a healthy lifestyle, jointly promoting the development of breast cancer treatment towards more individualized and precise directions. Let us work together to light the way for breast cancer patients and create a healthy and bright future!